Cevec Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation, a leading manufacturer of pharmaceutical products based in Seoul, South Korea announced today the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilise Cevec’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.
CAP-T™ CAP® cells are immortalised cell lines for transient and stable protein production developed by Cevec. These non-tumour origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.
“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression systems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases “ stated Wolfgang Kintzel, CEO at Cevec.
Dr Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of Cevec’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."